Cochrane Abstracts
Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Interferons‐beta Versus Glatiramer Acetate for Relapsing‐remitting Multiple Sclerosis." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437506/all/Interferons‐beta_versus_glatiramer_acetate_for_relapsing‐remitting_multiple_sclerosis.
Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437506/all/Interferons‐beta_versus_glatiramer_acetate_for_relapsing‐remitting_multiple_sclerosis. Accessed December 7, 2024.
Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437506/all/Interferons‐beta_versus_glatiramer_acetate_for_relapsing‐remitting_multiple_sclerosis
Interferons‐beta Versus Glatiramer Acetate for Relapsing‐remitting Multiple Sclerosis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 07]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437506/all/Interferons‐beta_versus_glatiramer_acetate_for_relapsing‐remitting_multiple_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
ID - 437506
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437506/all/Interferons‐beta_versus_glatiramer_acetate_for_relapsing‐remitting_multiple_sclerosis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
